Impact Education, LLC

ManagedCareHemo.com Presents A Rare Disease Strategy for the Evolving Hemophilia Treatment and Care Management Ecosystem

Jointly provided by

This activity is supported by independent educational grants from Sanofi Genzyme, Novo Nordisk, Inc., and Spark Therapeutics, Inc.

Webcast Complete!
Check back soon at www.ManagedCareHemo.com for the certified CE archive.

LEARN ABOUT

Evidence-based treatment modalities
Recently available and innovative therapies
Rare disease payer strategies and care management approaches
Collaborative partnerships among managed care and specialty pharmacy professionals with HTCs and affiliated providers

EXPERT FACULTY PRESENTERS

	James T. Kenney, RPh, MBA Founder and President JT Kenney, LLC		Marla Feinstein, PhD, MPH Senior Policy & Healthcare Analyst National Hemophilia Foundation
	Track 1 Mark T. Reding, MD Associate Professor of Medicine Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center		Track 2 Shannon L. Carpenter, MD, MSCI, FAAP Professor of Pediatrics, UMKC School of Medicine Hematology/Oncology, Director Kansas City Regional Hemophilia Treatment Center Director, Anticoagulation Management Program Children’s Mercy Hospital

TARGET AUDIENCE

The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

PROGRAM OVERVIEW

This activity can help managed care organizations and other payer types be better prepared to address the mounting challenges associated with rare, high-cost conditions such as hemophilia by formulating a comprehensive rare disease strategy. In doing so, it is necessary for payers to strike the appropriate balance between the urgency to respond to patient needs and the interpretation and application of the latest evidenced-based data while considering financial impact, value, and affordability, along with variation in coverage and its effects on access. This activity is designed to address these needs in order to improve clinical, economic, and humanistic outcomes for patients with hemophilia.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:

Track 1

Review current and emerging evidence-based treatment modalities
Employ collaborative partnerships among managed care and specialty pharmacy professionals with HTCs and affiliated providers to deliver optimal care for plan members with hemophilia

Track 2

Discuss alignment of recently available and innovative therapies in the evolving hemophilia treatment algorithm
Assess rare disease payer strategies and care management approaches for optimal outcomes specific to hemophilia

AGENDA

Track 1: Hemophilia Treatment and Care Management Updates – How to Improve the Quality and Cost of Care

Presentation	Faculty
Pre-Activity Learning Assessment and Opening Comments/Overview	James Kenney, RPh, MBA
Assessing the Latest Clinical Evidence and Guideline-Based Recommendations for Current and Emerging Therapies	Mark Reding, MD
Collaborative Partnerships with Hemophilia Treatment Centers to Deliver Optimal Care for Plan Members with Hemophilia	James Kenney, RPh, MBA
Audience Question and Answer Session, Key Takeaways, and Closing Comments	All

Track 2: Rare Disease Payer Strategy Recommendations for Hemophilia

Presentation	Faculty
Pre-Activity Learning Assessment and Opening Comments/Overview	James Kenney, RPh, MBA
Key Components of a Rare Disease Payer Strategy for Hemophilia	Shannon L. Carpenter, MD, MSCI, FAAP Marla Feinstein, PhD, MPH James Kenney, RPh, MBA
Hemophilia Case Scenarios using a Rare Disease Payer Strategy	Shannon L. Carpenter, MD, MSCI, FAAP Marla Feinstein, PhD, MPH James Kenney, RPh, MBA
Audience Question and Answer Session, Key Takeaways, and Closing Comments	All

ACCREDITATION INFORMATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Hemophilia Foundation, and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education (per track)
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: Hemophilia Treatment and Care Management Updates – How to Improve the Quality and Cost of Care - 1.5 AMA PRA Category 1 Credits™
Track 2: Rare Disease Payer Strategy Recommendations for Hemophilia - 1.5 AMA PRA Category 1 Credits™

Continuing Pharmacy Education (per track)
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1: Hemophilia Treatment and Care Management Updates – How to Improve the Quality and Cost of Care - 1.5 contact hours (0.15 CEUs)
Universal Activity Number: JA0003680-9999-22-001-L01-P
Type of Activity: Knowledge

Track 2: Rare Disease Payer Strategy Recommendations for Hemophilia - 1.5 contact hours (0.15 CEUs)
Universal Activity Number: JA0003680-9999-22-002-L01-P
Type of Activity: Knowledge

Continuing Nursing Education (per track)
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Track 1: Hemophilia Treatment and Care Management Updates – How to Improve the Quality and Cost of Care - 1.5 contact hours
Track 2: Rare Disease Payer Strategy Recommendations for Hemophilia - 1.5 contact hours

Disclosure of Conflicts of Interest
Medical Education Resources (MER) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.